Cell line · CVCL_0297
Papers32
1 to 20 of 32
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Hsa_Circ_0000615-Encoded 250-Amino Acid Polypeptide Suppresses Epithelial Ovarian Cancer Progression via Promoting HMGB1 Nuclear Accumulation. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The central precocious puberty-associated gene MKRN3 is a tumor suppressor regulating CSDE1 ubiquitination in ovarian cancer. | Oncogenesis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Disruption of the SNRPF-DDX24-E2F4 Feedback Loop Uncouples Splicing and Transcriptional Regulation to Suppress Ovarian Cancer Progression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Tumor-homing nanoplatform for the co-delivery of triptolide and siRNA-A4B2 conspicuously overcomes peritoneum metastasis of ovarian cancer. | Cell Oncol (Dordr) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Laeverin is Cell-Surface Target for Liquid-Phase Metastasizing Cancer Cells. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer. | Transl Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serum metabolic fingerprints encode functional biomarkers for ovarian cancer diagnosis: a large-scale cohort study. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial-Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Function of m5C RNA methyltransferase NOP2 in high-grade serous ovarian cancer. | Cancer Biol Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation. | Transl Oncol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. | Cell Rep | 2018 | Cellosaurus cites it | PubMed | |
| CD95/Fas ligand mRNA is toxic to cells. | Elife | 2018 | Its Methods give the RRID and name the line | PubMed | |
| Many si/shRNAs can kill cancer cells by targeting multiple survival genes through an off-target mechanism. | Elife | 2017 | Its Methods give the RRID and name the line | PubMed | |
| Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. | Cancer Cell | 2017 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0297/papers